---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030662"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:48:34.483417+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical Q2 revenue up 48% to $29.9M; posts positive Adjusted EBITDA of $0.5M

## Summary
- Revenue $29.9M, +48% YoY; gross margin 62.1% (+50 bps); net loss $3.9M ($0.03/sh) vs $2.2M loss year ago.
- Fifth consecutive quarter of positive Adjusted EBITDA: $0.5M vs $0.1M in prior year quarter.
- Launched SimpliGraft and SimpliMax amniotic membrane allografts; added 15 new distributors and 20 IDN contracts in Q2.
- Entered $5.0M private placement at $0.64/share on August 7, 2024; cash $5.4M at June 30, 2024.
- Reaffirms FY2024 revenue guidance $116M-$120M (27%-31% annual growth).

## SEC filing metadata
- accession: 0001493152-24-030662
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315224030662/0001493152-24-030662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315224030662/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030662
- JSON: https://secwatch.observer/filing/0001493152-24-030662.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.